1.Successful Treatment of Enterocutaneous Fistula in a Hemodialysis Patient with Somatostatin.
Ahmet Alper KIYKIM ; Bulent UYAR ; Tuna KATIRCIBASI ; Koray OCAL ; Altan YILDIZ ; Caner OZER
Yonsei Medical Journal 2009;50(6):865-866
Although cysticercosis is the most common parasitic disease affecting the central nervous system, spinal cysticercosis is rare. A rare form of spinal cysticercosis involving the whole spinal canal is presented. A 45-year-old Korean male had a history of intracranial cysticercosis and showed progressive paraparesis. Spinal magnetic resonance scan showed multiple cysts compressing the spinal cord from C1 to L1. Three different levels (C1-2, T1-3, and T11-L1) required operation. Histopathological examination confirmed cysticercosis. The patient improved markedly after surgery.
Adult
;
Female
;
Hormones/adverse effects/*therapeutic use
;
Humans
;
Intestinal Fistula/*drug therapy/etiology
;
Male
;
Middle Aged
;
Renal Dialysis/*adverse effects
;
Somatostatin/adverse effects/*therapeutic use
2.Clinical efficacy of letrozole in boys with idiopathic central precocious puberty.
Chinese Journal of Contemporary Pediatrics 2014;16(4):397-400
OBJECTIVETo investigate the efficacy of letrozole for delaying bone maturation and increasing predicted adult height in boys with idiopathic central precocious puberty (ICPP) who have a bone age above 13 years and a short stature, and its adverse effects.
METHODSTwenty ICPP boys with a bone age above 13 years and a short stature were randomly divided into letrozole treatment (n=10) and control groups (n=10). The letrozole treatment group received oral letrozole [2.5 mg/(m(2)·d), Qd] for 6 months, while the control group received no treatment and was observed periodically. Bone age, growth rate, height standard deviation (SD) score, predicted adult height SD score, sexual maturity, and levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), dehydroepiandrosterone, testosterone (T), estradiol (E2), progesterone (P), and androstenedione (ASD) were measured. The letrozole-related adverse reactions were evaluated.
RESULTSAfter 6 months of treatment, both groups had a significantly increased bone age, but the letrozole group had a significantly slowed increase in bone age compared with the control group (13.82 ± 0.23 years vs 14.47 ± 0.30 years; P<0.05); compared with the control group, the letrozole group had a significantly increased predicted adult height SD score (-1.69 ± 0.26 vs -1.91 ± 0.35; P<0.05) and a significantly increased T level (4.9 ± 0.9 nmol/L vs 4.4 ± 0.8 nmol/L; P<0.05). There was no significant difference in testicular volume between the two groups. The treatment led to no significant changes in growth rate, Tanner stage, and levels of FSH, LH, P, E2 and ASD in the two groups, and there was no significant difference in these indices between the two groups. No adverse reactions were observed during letrozole treatment.
CONCLUSIONSLetrozole delays bone maturation and increases predicted adult height in ICPP boys with a bone age above 13 years and a short stature, and it causes no obvious adverse reactions.
Adolescent ; Aromatase Inhibitors ; therapeutic use ; Body Height ; drug effects ; Bone Development ; drug effects ; Gonadal Steroid Hormones ; blood ; Humans ; Male ; Nitriles ; adverse effects ; therapeutic use ; Puberty, Precocious ; blood ; drug therapy ; Testis ; drug effects ; pathology ; Triazoles ; adverse effects ; therapeutic use
3.Pharmaceutical care for severe and critically ill patients with COVID-19.
Saiping JIANG ; Lu LI ; Renping RU ; Chunhong ZHANG ; Yuefeng RAO ; Bin LIN ; Rongrong WANG ; Na CHEN ; Xiaojuan WANG ; Hongliu CAI ; Jifang SHENG ; Jianying ZHOU ; Xiaoyang LU ; Yunqing QIU
Journal of Zhejiang University. Medical sciences 2020;49(2):158-169
Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on ( 6), and -19: , we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients.
Adrenal Cortex Hormones
;
adverse effects
;
therapeutic use
;
Anti-Bacterial Agents
;
therapeutic use
;
Antiviral Agents
;
adverse effects
;
therapeutic use
;
Betacoronavirus
;
isolation & purification
;
Coronavirus Infections
;
drug therapy
;
Critical Illness
;
Drug Therapy
;
Humans
;
Nutritional Support
;
Pandemics
;
Pneumonia, Viral
;
drug therapy
;
Probiotics
;
administration & dosage
4.Use and misuse of thyroid hormone.
Duncan Jake TOPLISS ; Shui Boon SOH
Singapore medical journal 2013;54(7):406-410
Synthetic thyroxine has replaced animal thyroid gland extract as the preferred drug in chronic thyroid hormone replacement. Synthetic thyroxine monotherapy is used to treat overt primary and secondary hypothyroidism, and some cases of subclinical hypothyroidism. In addition, thyroid-stimulating hormone suppressive therapy with thyroxine is a component of the chronic treatment for differentiated thyroid carcinoma. Liothyronine, however, is conventionally for short-term usage, including thyroid hormone withdrawal preparation for radioactive iodine scanning and treatment of differentiated thyroid carcinoma and some cases of myxoedema coma. On very rare occasions where patients are apparently intolerant of or unresponsive to thyroxine, liothyronine may be used chronically. However, there is controversy concerning the use of alternative regimens of thyroid hormone, such as the use of thyroxine-liothyronine combination and thyroid extracts. Thyroid hormone has also been misused to promote weight loss and treat 'symptomatic' biochemically euthyroid patients. There is insufficient evidence to support the use of thyroid hormone to improve treatment response in depression and severe non-thyroidal illnesses.
Animals
;
Depression
;
drug therapy
;
Hormone Replacement Therapy
;
adverse effects
;
methods
;
Humans
;
Hypothyroidism
;
drug therapy
;
Thyroid Function Tests
;
Thyroid Hormones
;
adverse effects
;
therapeutic use
;
Thyroid Neoplasms
;
drug therapy
6.Novel progress on treatment of acute graft-versus-host disease.
Ying ZHOU ; Bao-An CHEN ; Gang ZHAO
Journal of Experimental Hematology 2010;18(1):238-241
Acute graft-versus-host disease (aGVHD) is a common complication after allogeneic hematopoietic stem-cell transplantation. Despite improvements in understanding of transplant immunology, aGVHD remains to be a major cause of mortality for patients after allogeneic hematopoietic stem-cell transplantation. While systemic corticosteroid is standard primary therapy for aGVHD, there is no established standard treatment for patients in the steroid-refractory setting. Over the past decade, monoclonal antibodies, biologic engineering products, and chemotherapeutics with immunomodulatory effects are being used as novel therapies in this disease. Many of these agents, such as mycophenolate mofetil, anti-tumor necrosis factor antibodies, and anti-interleukin-2Ralpha-chain antibodies, have demonstrated promising activity in steroid-refractory aGVHD. But long-term survival remains poor due to a high incidence of infections. The key to improving aGVHD outcomes may, in fact, rest upon successful initial therapy, and timely taper corticosteroids to promote immune reconstitution. Clinical trials combining these newer agents with systemic corticosteroids as initial treatment are under way. In this article some new treatments for acute aGVHD are recommend and summarized.
Adrenal Cortex Hormones
;
therapeutic use
;
Antibodies, Monoclonal
;
therapeutic use
;
Graft vs Host Disease
;
therapy
;
Hematopoietic Stem Cell Transplantation
;
adverse effects
;
Humans
7.Sympathetic ophthalmia in an infected post-scleral buckling eye.
Jona M B SY-ONGKEKO ; Archimedes L D AGAHAN ; Juan S LOPEZ ; Jacinto U DY-LIACCO
Annals of the Academy of Medicine, Singapore 2011;40(3):147-148
Adrenal Cortex Hormones
;
therapeutic use
;
Aged
;
Anti-Infective Agents
;
therapeutic use
;
Anti-Inflammatory Agents
;
therapeutic use
;
Atropine
;
therapeutic use
;
Dexamethasone
;
therapeutic use
;
Eye Infections
;
complications
;
drug therapy
;
Female
;
Fluoroquinolones
;
therapeutic use
;
Glucocorticoids
;
therapeutic use
;
Humans
;
Mydriatics
;
therapeutic use
;
Ophthalmia, Sympathetic
;
drug therapy
;
etiology
;
Prednisolone
;
therapeutic use
;
Scleral Buckling
;
adverse effects
;
Triamcinolone
;
therapeutic use
8.Recombinant human thrombopoietin in combination with cyclosporin A as a novel therapy in corticosteroid-resistant primary immune thrombocytopenia.
Zhong-Guang CUI ; Xin-Guang LIU ; Ping QIN ; Ming HOU ; Shao-Ling WU ; Jun PENG ; Hong-Guo ZHAO ; Hong-Yi WANG ; Chun-Ting ZHAO
Chinese Medical Journal 2013;126(21):4145-4148
BACKGROUNDThe management of patients with refractory immune thrombocytopenia (ITP) is challenging, as there is no standard treatment option. The aim of this study was to investigate the efficacy of recombinant human thrombopoietin (rhTPO) in combination with cyclosporin A (CsA) for the management of patients with corticosteroid-resistant primary ITP.
METHODSThirty-six patients with corticosteroid-resistant ITP were randomly divided into an observation group and control group. In the observation group, 19 patients received subcutaneous injection of rhTPO at a dose of 1 µg/kg (300 U/kg) once daily up to day 14. Simultaneously they also received oral CsA at a dose of 1.5-2.0 mg/kg twice daily for three months. In the control group, rhTPO alone was administered subcutaneously at 1 µg/kg once daily in the other 17 ITP patients for 14 consecutive days and then the treatment was withdrawn.
RESULTSThere was no significant difference in the response rate at the end of the first week after treatment initiation between the observation group and the control group (63.2% vs. 58.8%, P > 0.05), neither was there at the end of the second week (89.5% vs. 94.1%, P > 0.05). However, the relapse rate in the observation group was significantly lower than that in control group at the end of the first (17.7% vs. 50.0%, P < 0.05), second (29.4% vs. 68.8%, P < 0.05) and the third month (29.4% vs. 87.5%, P < 0.01). In addition, rhTPO plus CsA were well tolerated and adverse events recorded were mild.
CONCLUSIONSCombination therapy with rhTPO and CsA was effective in the management of patients with corticosteroidresistant ITP, with a relatively short time to response and low recurrence rate. It might be considered as a potential secondline treatment regimen for ITP.
Adolescent ; Adrenal Cortex Hormones ; therapeutic use ; Adult ; Aged ; Cyclosporine ; administration & dosage ; therapeutic use ; Drug Resistance ; Female ; Humans ; Male ; Middle Aged ; Recombinant Proteins ; therapeutic use ; Thrombocytopenia ; drug therapy ; Thrombopoietin ; adverse effects ; therapeutic use ; Treatment Outcome ; Young Adult
9.Prevention and Treatment of Corticosteroid-Induced Osteoporosis.
Jun IWAMOTO ; Tsuyoshi TAKEDA ; Yoshihiro SATO
Yonsei Medical Journal 2005;46(4):456-463
Osteoporosis is one of the most serious complications of corticosteroid treatment. Loss of bone mineral density (BMD) and fractures occur early in the course of corticosteroid treatment, and thus early recognition of fracture risk and effective intervention based on evidence-based-medicine (EBM) are needed. A study of meta-analysis representing the highest level in a hierarchy of evidence showed that when the outcome measure of interest was limited to changes in lumbar spine BMD, bisphosphonates were the most effective of the agents studied in comparison with no therapy or treatment with calcium, and were also more efficacious than either vitamin D or calcitonin; the efficacy of bisphosphonates was enhanced when used in combination with vitamin D. Randomized controlled trials (RCTs) representing the second level in a hierarchy of evidence showed that bisphosphonates stabilized BMD not only in the lumbar spine, but also in the hip, and that parathyroid hormone (PTH) markedly increased lumbar spine BMD. According to the EBM, bisphosphonates and possibly PTH are suggested to be the most efficacious for preserving BMD. The efficacy of these agents in reducing the incidence of vertebral fractures in patients exposed to corticosteroids remains to be established in meta-analysis studies, although some RCTs have demonstrated the anti-fracture effects of etidronate, alendronate, and risedronate in the spine. Further RCTs of fracture prevention conducted on a large number of patients and their meta-analysis are needed to confirm the efficacy of bisphosphonates, PTH, or other agents in preventing vertebral and nonvertebral fractures.
Adrenal Cortex Hormones/*adverse effects
;
Bone Density
;
Diphosphonates/therapeutic use
;
Estrogens/therapeutic use
;
Humans
;
Osteoporosis/*chemically induced/*drug therapy/prevention & control
;
Parathyroid Hormone/therapeutic use
;
Vitamin K 2/therapeutic use
10.Outcome Predictors for Intestinal Behcet's Disease.
Jae Jun PARK ; Won Ho KIM ; Jae Hee CHEON
Yonsei Medical Journal 2013;54(5):1084-1090
Behcet's disease (BD) is a multisystem inflammatory disorder that presents as recurrent oral and genital ulcers in conjunction with other dermatological and ocular manifestations. The prevalence of BD is higher in Middle and East Asia than in Western countries. Intestinal BD is a specific subtype of BD, characterized by intestinal ulcers and associated gastrointestinal symptoms. Similar to inflammatory bowel disease, intestinal BD exhibits a fluctuating disease course with repeated episodes of relapse and remission that necessitate adequate maintenance therapy after achievement of clinical remission. Medical treatment of intestinal BD is largely empirical since well-controlled studies have been difficult to perform due to the heterogeneity and rarity of the disease. To date, 5-aminosalicylic acid, systemic corticosteroids, and immunosuppressants have been used anecdotally to treat intestinal BD. The clinical course of intestinal BD shows considerable variability, and the exact point at which more potent agents such as immunosuppressants should be used has not yet been elucidated. Given the difficulty in predicting which patients will experience complicated disease courses and the fact that these drugs are related with certain risk resulting from immunosuppression, proper identification of prognostic factors in intestinal BD may allow physicians to implement tailored medical therapy and individualized patient monitoring based on risk stratification. In this review, the impact of baseline characteristics on the long-term course of intestinal BD, prognostic factors during various medical therapies, and outcome predictors related to surgery will be discussed.
Adrenal Cortex Hormones/adverse effects/therapeutic use
;
Adult
;
Age Factors
;
Behcet Syndrome/*diagnosis/pathology/therapy
;
Female
;
Humans
;
Immunosuppressive Agents/adverse effects/therapeutic use
;
Immunotherapy
;
Intestinal Diseases/*diagnosis/pathology/therapy
;
Male
;
Prognosis
;
Sex Factors